Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes
Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervo...
Gespeichert in:
| Veröffentlicht in: | Medical science monitor. Basic research 2014-07, Vol.20, p.112-117 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 117 |
|---|---|
| container_issue | |
| container_start_page | 112 |
| container_title | Medical science monitor. Basic research |
| container_volume | 20 |
| creator | Komsuoglu Celikyurt, Ipek Mutlu, Oguz Ulak, Guner Uyar, Emre Bektaş, Emine Yildiz Akar, Furuzan Erden, Faruk Tarkun, Ilhan |
| description | Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model.
Modified elevated plus-maze test for anxiolytic-like, forced swimming test for depression-like behavior and hotplate test for neuropathy were used as behavioral tasks. Behavioral parameters were investigated in a streptozocin--(100 mg/kg, i.p.) and nicotinamide--(240 mg/kg, i.p.) induced type-2 diabetic mouse model. Exenatide (0.1 µg/kg, s.c., twice daily) was administered for 2 weeks. Vehicle (control), diabetic, and exenatide-treated diabetic mice were tested.
Our results confirm that exenatide exerts anxiolytic- and antidepressant-like effects and might be effective in diabetic neuropathy in a diabetic mouse model.
Exenatide may be a good candidate as a treatment option for depression, anxiety, and neuropathy in patients with type-2 diabetes. |
| doi_str_mv | 10.12659/MSMBR.891168 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4138071</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>25076419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-153ffe1d50543b61616392efae9087f88331e52740002972ec68090d1cb3f9a3</originalsourceid><addsrcrecordid>eNpVUV1LwzAUDaK4Mffoq-QPRPPRj-RF0DE_YEPQvZe0vXXRri1JNtZXf7lx0zFzSe6BnJzLyUHoktFrxpNY3czf5vev11IxlsgTNOSCxySKWHJ6hAdo7NwHDUumqeLpORrwmKZJxNQQfU230GhvSsDegvYraDyGLVjvsG62pq17bwoScBn2D6-z4FyApDafgKGqoNhxS2xhA9aBww2sbdtpv-yxabDGq3btIJwl1LitsO87IByXRufgwV2gs0rXDsa_fYQWD9PF5InMXh6fJ3czUgiZesJiEWaxMqZxJPKEhRKKQ6VBBWOVlEIwiHkaBaNcpRyKRFJFS1bkolJajNDtXrZb5ysoi2DU6jrrrFlp22etNtn_m8Yss_d2k0VMSJqyIED2AoVtnbNQHd4ymu3iyHZxZPs4Av_qeOCB_ff54hvuLojn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Komsuoglu Celikyurt, Ipek ; Mutlu, Oguz ; Ulak, Guner ; Uyar, Emre ; Bektaş, Emine ; Yildiz Akar, Furuzan ; Erden, Faruk ; Tarkun, Ilhan</creator><creatorcontrib>Komsuoglu Celikyurt, Ipek ; Mutlu, Oguz ; Ulak, Guner ; Uyar, Emre ; Bektaş, Emine ; Yildiz Akar, Furuzan ; Erden, Faruk ; Tarkun, Ilhan</creatorcontrib><description>Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model.
Modified elevated plus-maze test for anxiolytic-like, forced swimming test for depression-like behavior and hotplate test for neuropathy were used as behavioral tasks. Behavioral parameters were investigated in a streptozocin--(100 mg/kg, i.p.) and nicotinamide--(240 mg/kg, i.p.) induced type-2 diabetic mouse model. Exenatide (0.1 µg/kg, s.c., twice daily) was administered for 2 weeks. Vehicle (control), diabetic, and exenatide-treated diabetic mice were tested.
Our results confirm that exenatide exerts anxiolytic- and antidepressant-like effects and might be effective in diabetic neuropathy in a diabetic mouse model.
Exenatide may be a good candidate as a treatment option for depression, anxiety, and neuropathy in patients with type-2 diabetes.</description><identifier>ISSN: 2325-4416</identifier><identifier>ISSN: 2325-4394</identifier><identifier>EISSN: 2325-4416</identifier><identifier>DOI: 10.12659/MSMBR.891168</identifier><identifier>PMID: 25076419</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Animal Studies ; Animals ; Anti-Anxiety Agents - pharmacology ; Anti-Anxiety Agents - therapeutic use ; Antidepressive Agents - pharmacology ; Antidepressive Agents - therapeutic use ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - physiopathology ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetic Neuropathies - drug therapy ; Diabetic Neuropathies - physiopathology ; Disease Models, Animal ; Immobilization ; Male ; Maze Learning - drug effects ; Mice, Inbred BALB C ; Motor Activity - drug effects ; Peptides - pharmacology ; Peptides - therapeutic use ; Reaction Time - drug effects ; Time Factors ; Venoms - pharmacology ; Venoms - therapeutic use</subject><ispartof>Medical science monitor. Basic research, 2014-07, Vol.20, p.112-117</ispartof><rights>Med Sci Monit, 2014 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-153ffe1d50543b61616392efae9087f88331e52740002972ec68090d1cb3f9a3</citedby><cites>FETCH-LOGICAL-c387t-153ffe1d50543b61616392efae9087f88331e52740002972ec68090d1cb3f9a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138071/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138071/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25076419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Komsuoglu Celikyurt, Ipek</creatorcontrib><creatorcontrib>Mutlu, Oguz</creatorcontrib><creatorcontrib>Ulak, Guner</creatorcontrib><creatorcontrib>Uyar, Emre</creatorcontrib><creatorcontrib>Bektaş, Emine</creatorcontrib><creatorcontrib>Yildiz Akar, Furuzan</creatorcontrib><creatorcontrib>Erden, Faruk</creatorcontrib><creatorcontrib>Tarkun, Ilhan</creatorcontrib><title>Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes</title><title>Medical science monitor. Basic research</title><addtitle>Med Sci Monit Basic Res</addtitle><description>Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model.
Modified elevated plus-maze test for anxiolytic-like, forced swimming test for depression-like behavior and hotplate test for neuropathy were used as behavioral tasks. Behavioral parameters were investigated in a streptozocin--(100 mg/kg, i.p.) and nicotinamide--(240 mg/kg, i.p.) induced type-2 diabetic mouse model. Exenatide (0.1 µg/kg, s.c., twice daily) was administered for 2 weeks. Vehicle (control), diabetic, and exenatide-treated diabetic mice were tested.
Our results confirm that exenatide exerts anxiolytic- and antidepressant-like effects and might be effective in diabetic neuropathy in a diabetic mouse model.
Exenatide may be a good candidate as a treatment option for depression, anxiety, and neuropathy in patients with type-2 diabetes.</description><subject>Animal Studies</subject><subject>Animals</subject><subject>Anti-Anxiety Agents - pharmacology</subject><subject>Anti-Anxiety Agents - therapeutic use</subject><subject>Antidepressive Agents - pharmacology</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - physiopathology</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetic Neuropathies - drug therapy</subject><subject>Diabetic Neuropathies - physiopathology</subject><subject>Disease Models, Animal</subject><subject>Immobilization</subject><subject>Male</subject><subject>Maze Learning - drug effects</subject><subject>Mice, Inbred BALB C</subject><subject>Motor Activity - drug effects</subject><subject>Peptides - pharmacology</subject><subject>Peptides - therapeutic use</subject><subject>Reaction Time - drug effects</subject><subject>Time Factors</subject><subject>Venoms - pharmacology</subject><subject>Venoms - therapeutic use</subject><issn>2325-4416</issn><issn>2325-4394</issn><issn>2325-4416</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUV1LwzAUDaK4Mffoq-QPRPPRj-RF0DE_YEPQvZe0vXXRri1JNtZXf7lx0zFzSe6BnJzLyUHoktFrxpNY3czf5vev11IxlsgTNOSCxySKWHJ6hAdo7NwHDUumqeLpORrwmKZJxNQQfU230GhvSsDegvYraDyGLVjvsG62pq17bwoScBn2D6-z4FyApDafgKGqoNhxS2xhA9aBww2sbdtpv-yxabDGq3btIJwl1LitsO87IByXRufgwV2gs0rXDsa_fYQWD9PF5InMXh6fJ3czUgiZesJiEWaxMqZxJPKEhRKKQ6VBBWOVlEIwiHkaBaNcpRyKRFJFS1bkolJajNDtXrZb5ysoi2DU6jrrrFlp22etNtn_m8Yss_d2k0VMSJqyIED2AoVtnbNQHd4ymu3iyHZxZPs4Av_qeOCB_ff54hvuLojn</recordid><startdate>20140730</startdate><enddate>20140730</enddate><creator>Komsuoglu Celikyurt, Ipek</creator><creator>Mutlu, Oguz</creator><creator>Ulak, Guner</creator><creator>Uyar, Emre</creator><creator>Bektaş, Emine</creator><creator>Yildiz Akar, Furuzan</creator><creator>Erden, Faruk</creator><creator>Tarkun, Ilhan</creator><general>International Scientific Literature, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140730</creationdate><title>Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes</title><author>Komsuoglu Celikyurt, Ipek ; Mutlu, Oguz ; Ulak, Guner ; Uyar, Emre ; Bektaş, Emine ; Yildiz Akar, Furuzan ; Erden, Faruk ; Tarkun, Ilhan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-153ffe1d50543b61616392efae9087f88331e52740002972ec68090d1cb3f9a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animal Studies</topic><topic>Animals</topic><topic>Anti-Anxiety Agents - pharmacology</topic><topic>Anti-Anxiety Agents - therapeutic use</topic><topic>Antidepressive Agents - pharmacology</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - physiopathology</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetic Neuropathies - drug therapy</topic><topic>Diabetic Neuropathies - physiopathology</topic><topic>Disease Models, Animal</topic><topic>Immobilization</topic><topic>Male</topic><topic>Maze Learning - drug effects</topic><topic>Mice, Inbred BALB C</topic><topic>Motor Activity - drug effects</topic><topic>Peptides - pharmacology</topic><topic>Peptides - therapeutic use</topic><topic>Reaction Time - drug effects</topic><topic>Time Factors</topic><topic>Venoms - pharmacology</topic><topic>Venoms - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Komsuoglu Celikyurt, Ipek</creatorcontrib><creatorcontrib>Mutlu, Oguz</creatorcontrib><creatorcontrib>Ulak, Guner</creatorcontrib><creatorcontrib>Uyar, Emre</creatorcontrib><creatorcontrib>Bektaş, Emine</creatorcontrib><creatorcontrib>Yildiz Akar, Furuzan</creatorcontrib><creatorcontrib>Erden, Faruk</creatorcontrib><creatorcontrib>Tarkun, Ilhan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor. Basic research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Komsuoglu Celikyurt, Ipek</au><au>Mutlu, Oguz</au><au>Ulak, Guner</au><au>Uyar, Emre</au><au>Bektaş, Emine</au><au>Yildiz Akar, Furuzan</au><au>Erden, Faruk</au><au>Tarkun, Ilhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes</atitle><jtitle>Medical science monitor. Basic research</jtitle><addtitle>Med Sci Monit Basic Res</addtitle><date>2014-07-30</date><risdate>2014</risdate><volume>20</volume><spage>112</spage><epage>117</epage><pages>112-117</pages><issn>2325-4416</issn><issn>2325-4394</issn><eissn>2325-4416</eissn><abstract>Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model.
Modified elevated plus-maze test for anxiolytic-like, forced swimming test for depression-like behavior and hotplate test for neuropathy were used as behavioral tasks. Behavioral parameters were investigated in a streptozocin--(100 mg/kg, i.p.) and nicotinamide--(240 mg/kg, i.p.) induced type-2 diabetic mouse model. Exenatide (0.1 µg/kg, s.c., twice daily) was administered for 2 weeks. Vehicle (control), diabetic, and exenatide-treated diabetic mice were tested.
Our results confirm that exenatide exerts anxiolytic- and antidepressant-like effects and might be effective in diabetic neuropathy in a diabetic mouse model.
Exenatide may be a good candidate as a treatment option for depression, anxiety, and neuropathy in patients with type-2 diabetes.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>25076419</pmid><doi>10.12659/MSMBR.891168</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2325-4416 |
| ispartof | Medical science monitor. Basic research, 2014-07, Vol.20, p.112-117 |
| issn | 2325-4416 2325-4394 2325-4416 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4138071 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Animal Studies Animals Anti-Anxiety Agents - pharmacology Anti-Anxiety Agents - therapeutic use Antidepressive Agents - pharmacology Antidepressive Agents - therapeutic use Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - physiopathology Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Diabetic Neuropathies - drug therapy Diabetic Neuropathies - physiopathology Disease Models, Animal Immobilization Male Maze Learning - drug effects Mice, Inbred BALB C Motor Activity - drug effects Peptides - pharmacology Peptides - therapeutic use Reaction Time - drug effects Time Factors Venoms - pharmacology Venoms - therapeutic use |
| title | Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A44%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exenatide%20treatment%20exerts%20anxiolytic-%20and%20antidepressant-like%20effects%20and%20reverses%20neuropathy%20in%20a%20mouse%20model%20of%20type-2%20diabetes&rft.jtitle=Medical%20science%20monitor.%20Basic%20research&rft.au=Komsuoglu%20Celikyurt,%20Ipek&rft.date=2014-07-30&rft.volume=20&rft.spage=112&rft.epage=117&rft.pages=112-117&rft.issn=2325-4416&rft.eissn=2325-4416&rft_id=info:doi/10.12659/MSMBR.891168&rft_dat=%3Cpubmed_cross%3E25076419%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25076419&rfr_iscdi=true |